Optimizing response to gefitinib in the treatment of non-small-cell lung cancer

Figures & data

Figure 1 Frequency of main epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer.

Table 1 Phase III clinical trials of gefitinib versus chemotherapy in non-small-cell lung cancer patients harboring epidermal growth factor receptor (EGFR) mutations

Study (reference)	Treatment	N	Progression-free survival (months)		Hazard ratio (95% CI)	Overall survival (months)
			Gefitinib	Chemotherapy		Gefitinib	Chemotherapy
Subset analyses of subgroups of patients with EGFR mutations
IPASS^Citation31	First-line gefitinib vs carboplatin plus paclitaxel	261	9.5	6.3	0.48	21.6	21.9
First-SIGNAL^Citation32	First-line gefitinib vs gemcitabine plus cisplatin	42	8.5	6.7	0.61	30.6	26.5
Trials recruiting patients with EGFR mutations
WJTOG3405^Citation33	First-line gefitinib vs cisplatin plus docetaxel	172	9.2	6.3	0.489
NEJ002^Citation34	First-line gefitinib vs carboplatin plus paclitaxel	224	10.8	5.4	0.30	30.5	23.6

Table 2 Most frequent adverse events observed in non-small-cell lung cancer patients treated with gefitinib

Adverse event (all grade)	Frequency^a (%)
Rash	37–85
Liver dysfunction	55–70
Dry skin	11–54
Diarrhea	27–54
Asthenic conditions/fatigue	10–39
Paronychia	3–32
Stomatitis	6–22
Nausea	17–20
Constipation	10–16
Alopecia	3–11
Anorexia	5–22
Vomiting	13–15
Neutropenia	5–8
Interstitial lung disease	1–6

Notes:

a Data from IPASS, INTEREST, ISEL, NEJ002, and WJTOG3405 studies.^{6,21,30,33,34} Range of reported frequency.

Table 3 Frequency of adverse events occurring in non-small-cell lung cancer patients treated with gefitinib 250 mg/day in randomized Phase III clinical trials

Study	Treatment	N	Grade 1/4 (%)	Grade 3/4 (%)	Treatment discontinuation (%)
ISEL^Citation6	Gefitinib	1126	82	30	5
	Placebo	562	71	27	2
INTEREST^Citation21	Gefitinib	729	72	9	4
	Docetaxel	715	82	41	11
IPASS^Citation30	Gefitinib	607		28.7	6.9
	Carboplatin plus paclitaxel	589		61	13.6
NEJ002^Citation34	Gefitinib	114	94.7	41.2
	Carboplatin plus paclitaxel	113	97.3	71.7

YangCHFukuokaMMokTSFinal overall survival results from a phase III, randomised, open-label, first-line study of gefitinib vs carboplatin/paclitaxel in clinically selected patients with advanced non-small cell lung cancer in Asia (IPASS)Presented at European Society of Medical Oncology Meeting2010 (Abstract LBA2).

 Google Scholar

LeeJSParkKKimSWA randomized phase III study of gefitinib (IRESSA) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lungPresented at: World Conference on Lung Cancer2009 (Abstract PRS4).

 Google Scholar

MitsudomiTMoritaSYatabeYGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol201011212112820022809

 PubMed Web of Science ®Google Scholar

MaemondoMInoueAKobayashiKGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med2010362252380238820573926

 PubMed Web of Science ®Google Scholar

ThatcherNChangAParikhPGefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)Lancet200536694961527153716257339

 PubMed Web of Science ®Google Scholar

KimESHirshVMokTGefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialLancet200837296521809181819027483

 PubMed Web of Science ®Google Scholar

MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680

 PubMed Web of Science ®Google Scholar